Hepatitis C virus drug resistance-associated substitutions: State of the art summary. - Wikidata - awgldk - TriplyDB

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

http://www.wikidata.org/entity/Q38533619

about

Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals Virologic Tools for HCV Drug Resistance Testing Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance Hepatitis C Virus and Antiviral Drug Resistance State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Reinventing HCV Treatment: Past and Future Perspectives.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor.Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms.Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice.Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals.Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.Hepatitis C virus whole genome sequencing: Current methods/issues and future challenges.Safety of direct antiviral agents in the management of hepatitis C.Prevention and management of treatment failure to new oral hepatitis C drugs.Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Viral evasion and challenges of hepatitis C virus vaccine development.Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Management of direct antiviral agent failures.Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.Clinical Pharmacokinetics of Paritaprevir.

P2860

Q26740219-62D77C9F-8952-44F9-9630-BBF25B1CD23B Q26773321-3536B941-AAFA-4C3F-AF8F-89381E1BF3F6 Q26774374-08A84FCE-7E80-429C-A0B2-3BBDDD9812EC Q26775825-B81979BF-B411-4D35-971F-66A1F3587F2E Q26777408-A74E5E86-877B-4C3A-9E52-C4759FB9DA00 Q27469038-4BC1AF46-351A-4993-A425-833BED64A969 Q28067295-3FCF4D27-337A-42ED-85ED-E91638892BD3 Q28079102-0A2F78BA-CAC9-4F88-96E0-3A5BC984C273 Q28080225-2EA1A732-2DB3-4140-925B-65BAE3F175F0 Q30241881-F8C79CBC-552F-406B-A321-C905408E9398 Q30355190-3A701FAE-F67B-4208-AA03-C8D426403135 Q31042796-FF91E313-44EC-45E3-87AD-194A355F40A0 Q34506788-6839901F-577F-4640-A7B3-9E88022E9E26 Q34536770-B0AFF2F2-08A8-441F-AB89-25C9B33C007C Q35994877-6C4399CD-7DD6-4289-BFB3-012A6DADE710 Q36096436-5785087D-FC53-4935-8F61-DAB84A7D2155 Q36148440-85EEE683-8FF9-4CF0-B11F-8533A156404B Q36182240-CD0D2E91-1819-4B2C-9C28-B4E2040F1EA4 Q36290778-12A40B4E-0B46-4D42-879D-4F2A3DE3AF88 Q36347235-887BF3FA-1829-4FB0-AB35-DC5FA64E09E4 Q36446122-AB7CA181-5DAC-475F-901E-C6D11A7ADD02 Q36933403-BAF322B8-55C8-4DFE-B455-B1455525E911 Q37058681-9DFD4BC5-B81F-400A-A4BF-6037B987CA2A Q37286311-308A4064-7190-4D83-B7D9-3CAF345D3D59 Q37310564-F87541A8-1F86-4149-B64F-36B45953B937 Q37417999-9EF0C28E-EA98-4712-90D6-02A633A645DD Q37518390-C64ADA40-1B12-4539-BC66-065B3A69F7EB Q38715350-62A1936B-A031-48A9-A341-4A9C8A7439F5 Q38779980-AC5CBB44-A43D-4CE2-913E-9FD4A5F2E409 Q38805659-B224B202-7F92-47FA-86EC-4E80F166E984 Q38818416-74A3441E-4678-471C-AA93-36F5857649F7 Q38826624-87F086B2-9B62-4282-9457-A46A355B3C56 Q38860200-3B14312D-AB24-4C0E-A089-1DBCCE342DA9 Q38888859-858E3D17-234C-410E-B719-391D9EBECA3B Q38893104-257CECB7-93CB-4B74-8025-C28AE32438E1 Q38961608-5D388A87-A03E-46E1-9265-4EDCC3E6ADEE Q38972180-15C21102-933C-4559-815A-0D0836DF3CE1 Q39024201-48FE7C43-90E6-407A-9D60-044BA11FB849 Q39032538-B5BAAD01-77FD-4B92-8BC4-180FE054A128 Q39150134-674886ED-20E9-42E2-B638-81DD58F3A10F

P2860

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

http://www.wikidata.org/entity/Q38533619

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

@en

type

label

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

@en

prefLabel

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

@en

P1433

Q38533619-077E6191-2024-4292-B610-ABD8D08656C6

P1476

Q38533619-B7C7BA07-7E9A-434A-B2E4-6A31F13AAA4D

P2093

Q38533619-09693160-142B-4C1D-ACB5-A90895604A8C

Q38533619-17C29072-5246-4C72-96BE-9A0ECF66484B

Q38533619-386825A2-41F1-47C9-A434-63A7D0B8B8FE

Q38533619-3A11D30B-919A-4203-849E-12C46E7EBF8E

Q38533619-4BFD6D6B-55D2-4E31-AFDA-22649D95AA3D

Q38533619-5C10ED3D-F14B-4C43-B7EF-E64C57763E2D

Q38533619-7D888F63-DD59-47CE-8584-404AF204C278

Q38533619-82D93E87-F9DF-4736-AE04-9B022F3842F8

Q38533619-984C55CB-56F5-4C6F-811B-010C08F2FCAC

Q38533619-A62001CE-2E66-4821-AFCD-56142E871DF4

P2860

Q38533619-00D2CDD6-AADB-484B-9989-B3903F4FF580

Q38533619-0C9BCF31-C52B-4C88-A248-89A6465D9FC6

Q38533619-10F6F945-6A5B-4079-B982-EAA4285B16AD

Q38533619-1322D5B7-A028-4C5A-B7F9-ED7DA5970F4E

Q38533619-1398DBE9-0E70-434C-902B-A099284873F5

Q38533619-165DE44D-2A0D-4005-96E8-419C17FFEC08

Q38533619-18530AC2-2D75-415D-BAAB-D979B9E7B37B

Q38533619-193B483F-065A-4361-A926-111A75E6F259

Q38533619-212DF59D-8249-4896-AA02-12A95F79993A

Q38533619-2D1E584B-0BBE-4756-A181-43FA27A1FDE1

P304

Q38533619-54EA9325-605F-4E5C-A44E-80E5C3FF76C9

P31

Q38533619-6C8E446D-2B15-47E4-8F1D-E41E6EF28300

P356

Q38533619-F75188BC-0781-4ABE-9BAD-7E55B1009971

P407

Q38533619-683E78A5-1E2A-4329-BA01-AA8C57E6E97B

P433

Q38533619-46998183-3851-404F-8064-F987FFEE887C

P478

Q38533619-46AF9B68-8B0F-416C-B6F0-EB148F1CF68B

P50

Q38533619-E3C3BD25-304A-4C01-A46D-99EA0D1AF97E

P577

Q38533619-5F329DF2-EF15-46E6-A6F7-08431D744F6B

P698

Q38533619-1FF8C03D-5F35-45A0-9D77-564BCC6F3114

P356

P1433

P1476

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

@en

P2093

Anita Howe

http://www.w3.org/2001/XMLSchema#string

Erik Lontok

http://www.w3.org/2001/XMLSchema#string

Fiona McPhee

http://www.w3.org/2001/XMLSchema#string

Hongmei Mo

http://www.w3.org/2001/XMLSchema#string

Johan Lennerstrand

http://www.w3.org/2001/XMLSchema#string

Neil Parkin

http://www.w3.org/2001/XMLSchema#string

Oliver Lenz

http://www.w3.org/2001/XMLSchema#string

Patrick Harrington

http://www.w3.org/2001/XMLSchema#string

Tami Pilot-Matias

http://www.w3.org/2001/XMLSchema#string

Tara Kieffer

http://www.w3.org/2001/XMLSchema#string

P2860

Polymerase structures and function: variations on a theme?

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

P304

1623-1632

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.27934

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Tami Pilot-Matias

P577

2015-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26095927

http://www.w3.org/2001/XMLSchema#string